1.Preoperative selection of endometrial cancer patients at low risk for lymph node metastases: useful criteria for enrollment in clinical trials.
Mariam M ALHILLI ; Andrea MARIANI
Journal of Gynecologic Oncology 2014;25(4):267-269
No abstract available.
Endometrial Neoplasms/*surgery
;
Female
;
Humans
;
*Lymph Node Excision
3.Current landscape and future perspective of sentinel node mapping in endometrial cancer.
Giorgio BOGANI ; Francesco RASPAGLIESI ; Umberto LEONE ROBERTI MAGGIORE ; Andrea MARIANI
Journal of Gynecologic Oncology 2018;29(6):e94-
Endometrial cancer (EC) represents the most common gynecological neoplasm in developed countries. Surgery is the mainstay of treatment for EC. Although EC is characterized by a high prevalence several features regarding its management are still unclear. In particular the execution of lymphadenectomy is controversial. The recent introduction of sentinel node mapping represents the mid-way between the execution and omission of node dissection in EC patients. In the present review we discuss the emerging role of sentinel node mapping in EC. In addition, we discussed how type of tracers utilized and site of injection impacted on sentinel node detection rates. Future perspective regarding EC management are also discussed.
Developed Countries
;
Endometrial Neoplasms*
;
Female
;
Humans
;
Laparoscopy
;
Lymph Node Excision
;
Prevalence
;
Robotic Surgical Procedures
4.Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer.
Koji MATSUO ; Hiroko MACHIDA ; Andrea MARIANI ; Rachel S MANDELBAUM ; Gretchen E GLASER ; Bobbie S GOSTOUT ; Lynda D ROMAN ; Jason D WRIGHT
Journal of Gynecologic Oncology 2018;29(5):e69-
OBJECTIVE: To examine the trends and survival for women with early-stage epithelial ovarian cancer who underwent adequate lymphadenectomy during surgical treatment. METHODS: This is a retrospective observational study examining the Surveillance, Epidemiology, End Results program between 1988 and 2013. We evaluated 21,537 cases of stage I–II epithelial ovarian cancer including serous (n=7,466), clear cell (n=6,903), mucinous (n=4,066), and endometrioid (n=3,102) histology. A time-trend analysis of the proportion of patients who underwent adequate pelvic lymphadenectomy (≥ 8 per Gynecologic Oncology Group [GOG] criteria, ≥ 12 per Collaborative Group Report [CGR] criteria for bladder cancer, and > 22 per Mayo criteria for endometrial cancer) and a survival analysis associated with adequate pelvic lymphadenectomy were performed. RESULTS: There were significant increases in the proportion of women who underwent adequate lymphadenectomy: GOG criteria 3.6% to 28.6% (1988–2010); CGR criteria 2.4% to 22.4% (1988–2013); and Mayo criteria 0.7% to 9.5% (1988–2013) (all, p < 0.05). On multivariable analysis, adequate lymphadenectomy was independently associated with improved cause-specific survival compared to inadequate lymphadenectomy: GOG criteria, adjusted-hazard ratio (HR)=0.75, CGR criteria, adjusted-HR=0.77, and Mayo criteria, adjusted-HR = 0.85 (all, p < 0.05). Compared to inadequate lymphadenectomy, adequate lymphadenectomy was significantly associated with improved cause-specific survival for serous (HR range = 0.67–0.73), endometrioid (HR range = 0.59–0.61), and clear cell types (HR range = 0.66–0.73) (all, p < 0.05) but not in mucinous type (HR range = 0.80–0.91; p > 0.05). CONCLUSION: Quality of lymphadenectomy during the surgical treatment for early-stage epithelial ovarian cancer has significantly improved. Adequate lymphadenectomy is associated with a 15%–25% reduction in ovarian cancer mortality compared to inadequate lymphadenectomy.
Epidemiology
;
Female
;
Humans
;
Lymph Node Excision*
;
Mortality
;
Mucins
;
Observational Study
;
Ovarian Neoplasms*
;
Retrospective Studies
;
Urinary Bladder Neoplasms